Guillermo Morales
Principal investigator, leads SignalRx Pharmaceuticals Inc..
BiotechFounder
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2017First federal award
$2.6MFederal grants as PI3 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
3 awards · $2.6M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jun 10, 2019 | NIH | SBIR Phase I Overcoming BTK inhibitor resistance in B-cell malignancies | $300K | SignalRx Pharmaceuticals Inc. |
| Aug 20, 2018 | NIH | STTR Phase I Discovery of novel CDK4/6-PI3K-BRD4 inhibitor SRX3177 for augmented anti-cancer activity | $300K | SignalRx Pharmaceuticals Inc. with UNIVERSITY OF CALIFORNIA, SAN DIEGO |
| Jul 11, 2017 | NIH | STTR Phase II Development of the first-in-class novel dual PI-3K/BRD4 inhibitor SF2523 | $2.0M | SignalRx Pharmaceuticals Inc. with UNIVERSITY OF CALIFORNIA, SAN DIEGO |
Peer ranks
Federal funding#739
Awards as PI#822
Patents#273
Companies
- SignalRx Pharmaceuticals Inc.Leads (SEC Form D) · Biotech
Research institutions
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.